

Supplementary Table 7. Univariable and multivariable analysis of prognosis factors for RFS and OS among groups N0, A + B, and C

| Characteristic | Univariable analysis | | | Multivariable analysis | | |
|--|----------------------|---------|------------------|------------------------|---------|------------------|
| | RFS | | OS | RFS | | OS |
| | HR (95% CI) | P-value | HR (95% CI) | HR (95% CI) | P-value | P-value |
| Age (yr), >60 vs. ≤60 | 0.80 (0.51–1.24) | 0.310 | 1.03 (0.65–1.65) | - | - | - |
| Sex, female vs. male | 0.85 (0.55–1.30) | 0.444 | 0.74 (0.47–1.17) | - | - | - |
| Hemoglobin (g/L), >130 vs. ≤130 | 0.77 (0.50–1.18) | 0.232 | 0.89 (0.56–1.40) | - | - | - |
| Serum albumin (g/L), >35 vs. ≤35 | 0.82 (0.41–1.63) | 0.567 | 0.64 (0.31–1.34) | - | - | - |
| TBIL (μmol/L), >17.1 vs. ≤17.1 | 0.73 (0.45–1.20) | 0.221 | 0.99 (0.59–1.65) | - | - | - |
| ALT (U/L), >40 vs. ≤40 | 0.89 (0.57–1.40) | 0.617 | 1.14 (0.72–1.80) | - | - | - |
| γ-GT (U/L), >50 vs. ≤50 | 1.49 (0.87–2.54) | 0.148 | 1.81 (0.93–3.52) | - | - | - |
| PT (sec), >14 vs. ≤14 | 1.30 (0.48–3.56) | 0.607 | 1.82 (0.57–5.79) | - | - | - |
| INR, >1.15 vs. ≤1.15 | 2.17 (1.05–4.52) | 0.037 | 2.66 (1.21–5.84) | 1.47 (0.65–3.35) | 0.353 | 3.21 (1.37–7.54) |
| HBsAg, positive vs. negative | 1.44 (0.90–2.29) | 0.127 | 1.58 (0.97–2.56) | - | - | - |
| CEA (μg/L), >5 vs. ≤5 | 1.52 (0.99–2.33) | 0.057 | 1.60 (1.02–2.50) | - | - | 1.27 (0.74–2.18) |
| CA 125 (U/mL), >35 vs. ≤35 | 1.91 (1.24–2.93) | 0.003 | 2.02 (1.28–3.19) | 1.73 (1.08–2.79) | 0.023 | 1.82 (1.09–3.05) |
| CA 19-9 (U/mL), >35 vs. ≤35 | 2.68 (1.52–4.72) | 0.001 | 1.68 (0.98–2.89) | 3.00 (1.66–5.44) | <0.001 | - |
| Tumor number, >1 vs. 1 | 1.88 (1.12–3.17) | 0.018 | 1.47 (0.87–2.49) | 2.13 (1.22–3.70) | 0.007 | - |
| Tumor size (cm), >5 vs. ≤5 | 1.58 (1.01–2.49) | 0.046 | 1.31 (0.80–2.14) | 1.53 (0.79–2.96) | 0.212 | - |
| Tumor type, non-mass-forming vs. mass-forming | 1.94 (0.90–4.21) | 0.093 | 1.73 (0.75–3.98) | - | - | - |
| Surgical margin, R1 vs. R0 | 1.69 (0.77–3.70) | 0.187 | 2.25 (1.02–4.97) | - | - | 2.32 (1.01–5.36) |
| No. of LNs harvested, ≥6 vs. <6 | 1.06 (0.69–1.62) | 0.793 | 0.98 (0.62–1.53) | - | - | - |
| Vascular invasion, yes vs. no | 1.85 (1.13–3.03) | 0.014 | 1.55 (0.92–2.59) | 1.39 (0.83–2.35) | 0.213 | - |
| Surgery time (min), >300 vs. ≤300 | 1.15 (0.75–1.78) | 0.522 | 1.29 (0.82–2.03) | - | - | - |
| Blood loss (mL), >300 vs. ≤300 | 1.58 (1.03–2.42) | 0.037 | 1.27 (0.81–2.00) | 1.52 (0.96–2.40) | 0.075 | - |
| Blood transfusion, yes vs. no | 1.50 (0.96–2.35) | 0.077 | 1.35 (0.85–2.15) | - | - | - |
| Postoperative hospital stay (day), >12 vs. ≤12 | 1.57 (1.02–2.41) | 0.041 | 1.22 (0.77–1.91) | 1.04 (0.66–1.66) | 0.855 | - |
| Postoperative complication, yes vs. no | 0.96 (0.56–1.63) | 0.873 | 0.88 (0.50–1.55) | - | - | - |
| Adjuvant treatment, yes vs. no | 0.76 (0.37–1.57) | 0.457 | 0.80 (0.32–1.98) | - | - | - |
| Grouping factor | | | | | | |
| Group N0 | 1.00 | - | 1.00 | 1.00 | - | 1.00 |
| Group A + B | 1.49 (0.89–2.51) | 0.132 | 1.40 (0.80–2.46) | 0.92 (0.53–1.60) | 0.773 | 1.03 (0.56–1.93) |
| Group C | 2.94 (1.73–5.00) | <0.001 | 2.19 (1.28–3.74) | 2.10 (1.21–3.65) | 0.008 | 1.54 (0.86–2.76) |

RFS, recurrence-free survival; OS, overall survival; CI, confidence interval; HR, hazard ratio; TBIL, total bilirubin; INR, international normalized ratio; LN, lymph node.